DENISOV LEV ALEXANDROVICH,CHERNOVSKAYA TATYANA VENIAMINOVA,KLENOVA ANGELINA VSEVOLODOVNA,MOROZOV DMITRI VELANTINOVICH,RUDENKO ELENA GEORGIEVNA
申请号：
ARP110102606
公开号：
AR087227A1
申请日:
2011.07.19
申请国别(地区):
AR
年份:
2014
代理人:
摘要：
Relates to the field of pharmaceutical industry and medicine, particularly with the peg Derivatives of interferons and refers to the creation of an interferon conjugated with polyethylene glycol, functionally Active, highly Purified, stable, with the activity of interferon, immune Genicidad decreased.Prolonged improved Biological Action and pharmacokinetic parameters of common formula (1): integer values, where N - 227 to 10000 so that the molecular mass of Peg is approximately 10000 - 40000 da； M - integer value - 4； natural or recombinant IFN - polypeptide that possesses Act Ivity to IFN -.This also refers to Medicines containing the Conjugate of the formula (1), Pharmaceutical compositions, which can be applied for the treatment of Viral Diseases and cancer, accompanied by primary or secondary Immune Deficiency State, containing the Conjugated Peg IFN ancillary submitted and accepted.This refers to the application of the Conjugate of the formula (1) to obtain a drug with antiviral activity, antiproliferative and Immuno Modulated the method for prophylaxis and / or treatment of diseases accompanied with primary or second Immuno deficient State Aryan,Including the introduction of a therapeutically effective amount of the Conjugate of the formula (1), and the container comprising the pharmaceutical Composition and the corresponding set.Claim 1: The Stable conjugated pegylated interferon to formula (1), representing a single positional isomer, where: N integer values of M - 227 10000； integer value - 4； na h - IFN interferon -.Se relaciona con el ámbito de la industria farmacéutica y medicina, particularmente con los PEG-derivados de interferones y se refiere a la creación de un conjugado de interferón con polietilenglicol, funcionalmente activo, altamente depurado, estable, con la actividad del interferón a, inmunogenicidad disminuida, acción biológica prolongada y parámetros farmacocinéticas mejorados de fórmula común (1), donde: n - valores enteros de 227 a 10000
